CYTO logo

Altamira Therapeutics (CYTO)

Profile

Full Name

Altamira Therapeutics Ltd.

Ticker Symbol

CYTO

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Bermuda

IPO

August 6, 2014

Indexes

Not included

Website

http://altamiratherapeutics.com

Employees

10

Key Details

Price

$0.07(+16.47%)

Market cap

$264.50K(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$188.40K(-41.20% YoY)

Annual EPS

-$1.43(+99.77% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.07
CYTO price is $0.07

30-Day Relative Volume

0.02
CYTO 30-day relative volume is 0.02

Price Performance

Price Most recent change

+16.47%
CYTO price was up +16.47% on Apr 11, 2025

Price YTD change

-36.65%
CYTO price is down -36.65% since January 1st

Price 1-year change

-96.17%
CYTO price is down -96.17% year-on-year

Price 3-year change

-99.98%
CYTO price is down -99.98% over the past 3 years

Price Range

Price All-time high

$636800.00
CYTO price is currently -100.00% below its historical high of $636800.00

Price 3-year low

$0.05
CYTO price is currently +39.72% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$264.50K
CYTO market capitalization is $264.50 thousand

Market cap 3-year change

-98.32%
CYTO market capitalization is down -98.32% over the past 3 years

Market cap All-time high

$249.28M
CYTO market capitalization is currently -99.89% below its historical high of $249.28 million

Market cap sector rank

2.55%
CYTO market capitalization is higher than 2.55% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+68.67%
CYTO shares outstanding is up +68.67% year-on-year

Shares Outstanding 3-Year Change

+9791.36%
CYTO shares outstanding is up +9791.36% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

3.18
CYTO beta is 3.18

200-day SMA

$0.52
CYTO price is currently -86.59% below its 200-day simple moving average

50-day SMA

$0.10
CYTO price is currently -29.79% below its 50-day simple moving average

RSI

45.00
CYTO 14-day relative strength index is 45.00

Volume

0.02
CYTO 30-day relative volume is 0.02

ATR

$0.02
CYTO average true range is $0.02

10-day Historical Volatility

483.83%
CYTO 10-day historical volatility is 483.83%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$188.40K
CYTO annual revenue is $188.40 thousand

Revenue Analysts estimate

-
CYTO annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-41.2%
CYTO annual revenue is down -41.2% year-on-year

Revenue Sector rank

7.05%
CYTO annual revenue is higher than 7.05% of companies in Healthcare sector

EPS

EPS

-$1.43
CYTO annual earnings per share is -$1.43

EPS Analysts estimate

-$2.65
CYTO annual earnings per share is currently -45.90% lower than the consensus analysts' forecast

EPS 1-year change

+99.77%
CYTO annual earnings per share is up +99.77% year-on-year

EPS Sector rank

47.07%
CYTO annual earnings per share is higher than 47.07% of companies in Healthcare sector

Profit

Gross profit

-$80.60K
CYTO annual gross profit is -$80.60 thousand

Gross margin

-42.78%
CYTO annual gross profit margin is -42.78%

Operating profit

-$1.83M
CYTO annual operating income is -$1.83 million

Operating margin

-972.71%
CYTO annual operating profit margin is -972.71%

Net income

-$2.12M
CYTO annual net profit is -$2.12 million

Net margin

-1124.75%
CYTO annual net profit margin is -1124.75%

Expenses

Total expenses

$2.02M
CYTO annual total expenses is $2.02 million

Operating expenses

$1.75M
CYTO annual total operating expenses is $1.75 million

Cost of goods sold

$268.90K
CYTO annual cost of goods sold is $268.90 thousand

Selling, general & administrative expenses

$214.30K
CYTO annual SGA is $214.30 thousand

Depreciation and amortization

-
CYTO annual depreciation & amortization value is unknown

Interest expense

$362.40K
CYTO annual interest expense is $362.40 thousand

Income tax

-$117.70K
CYTO annual income tax is -$117.70 thousand

EBIT & EBITDA

EBIT

-$1.87M
CYTO annual earnings before interest & taxes is -$1.87 million

EBITDA

-$1.87M
CYTO annual EBITDA is -$1.87 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.76M
CYTO annual total assets is $1.76 million

Non current assets

$7.70M
CYTO annual long term assets is $7.70 million

Current assets

$1.46M
CYTO annual total current assets is $1.46 million

Cash and cash equivalents

$735.10K
CYTO annual cash & cash equivalents is $735.10 thousand

Accounts receivable

$119.50K
CYTO annual accounts receivable is $119.50 thousand

Inventory

$389.60K
CYTO annual inventory is $389.60 thousand

Liabilities

Total liabilities

$1.87M
CYTO annual total liabilities is $1.87 million

Long term liabilities

$412.70K
CYTO annual total long term liabilities is $412.70 thousand

Current liabilities

$1.06M
CYTO annual total current liabilities is $1.06 million

Accounts payable

$491.80K
CYTO annual accounts payable is $491.80 thousand

Debt

Total debt

$22.50K
CYTO annual total debt is $22.50 thousand

Total debt 1-year change

-99.67%
CYTO annual total debt is down -99.67% year-on-year

Long term debt

-
CYTO annual long term debt value is unknown

Short term debt

$22.50K
CYTO annual short term debt is $22.50 thousand

Equity & Capital

Shareholders equity

-$111.20K
CYTO annual stockholders equity is -$111.20 thousand

Book value

$7.69M
CYTO annual book value is $7.69 million

Retained earnings

-$21.48M
CYTO annual retained earnings is -$21.48 million

Working capital

$945.10K
CYTO annual working capital is $945.10 thousand

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$614.50K
CYTO annual cash flow from operations is -$614.50 thousand

Cash from operations 1-year change

+93.44%
CYTO annual cash flow from operations is up +93.44% year-on-year

Cash from investing

$2500.00
CYTO annual cash flow from investing activities is $2500.00

Cash from investing 1-year change

+100.11%
CYTO annual cash flow from investing activities is up +100.11% year-on-year

Cash from financing

$1.19M
CYTO annual cash flow from financing activities is $1.19 million

Cash from financing 1-year change

-88.77%
CYTO annual cash flow from financing activities is down -88.77% year-on-year

CAPEX

CAPEX

-
CYTO annual capital expenditures value is unknown

CAPEX 1-year change

-
CYTO annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$614.50K
CYTO annual free cash flow is -$614.50 thousand

Free cash flow 1-year change

+94.74%
CYTO annual free cash flow is up +94.74% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-42.78%
CYTO annual gross profit margin is -42.78%

Operating margin

-972.71%
CYTO annual operating profit margin is -972.71%

Net margin

-1124.75%
CYTO annual net profit margin is -1124.75%

ROA & ROE

ROA

-120.33%
CYTO annual return on assets is -120.33%

ROE

1905.22%
CYTO annual return on equity is 1905.22%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
CYTO price to earnings ratio value is unknown

PE ratio Sector rank

-
CYTO price to earnings ratio is unknown

PB Ratio

PB ratio

0.04
CYTO price to book ratio is 0.04

PB ratio Sector rank

17.02%
CYTO price to book ratio is higher than 17.02% of companies in Healthcare sector

PS Ratio

PS ratio

-
CYTO price to sales ratio value is unknown

PS ratio Sector rank

-
CYTO price to sales ratio is unknown

Enterprise value

Enterprise value

$626.50K
CYTO enterprise value is $626.50 thousand

Enterprise value Sector rank

13.46%
CYTO enterprise value is higher than 13.46% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-
CYTO EV/EBITDA value is unknown

EV/EBITDA Sector rank

-
CYTO EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.36
CYTO annual current ratio is 2.36

Quick ratio

1.01
CYTO annual quick ratio is 1.01

Leverage

Debt to equity

-0.20
CYTO annual debt to equity ratio is -0.20

Interest coverage ratio

-5.17
CYTO annual interest coverage ratio is -5.17

Risk & Stability

Piotroski F-Score

-
CYTO piotroski f-score value is unknown

Altman Z-Score

-19.76
CYTO altman z-score is -19.76

Analyst ratings

Recent major analysts updates

No data about analysts updates

Institutional Ownership

Similar stocks

RNAZ logo
TransCode Therapeutics (RNAZ)
VRPX logo
Virpax Pharmaceuticals (VRPX)
KRBP logo
Kiromic BioPharma (KRBP)
CUTR logo
Cutera (CUTR)
TCBP logo
TC Biopharm (Holdings) (TCBP)
IMAC Holdings (BACK)
STSS logo
Sharps Technology (STSS)
TCON logo
TRACON Pharmaceuticals (TCON)
HEPA logo
Hepion Pharmaceuticals (HEPA)
  • What is the ticker symbol for Altamira Therapeutics?
  • Does Altamira Therapeutics pay dividends?
  • What sector is Altamira Therapeutics in?
  • What industry is Altamira Therapeutics in?
  • What country is Altamira Therapeutics based in?
  • When did Altamira Therapeutics go public?
  • Is Altamira Therapeutics in the S&P 500?
  • Is Altamira Therapeutics in the NASDAQ 100?
  • Is Altamira Therapeutics in the Dow Jones?
  • When was Altamira Therapeutics's last earnings report?
  • When does Altamira Therapeutics report earnings?

What is the ticker symbol for Altamira Therapeutics?

The ticker symbol for Altamira Therapeutics is NASDAQ:CYTO

Does Altamira Therapeutics pay dividends?

No, Altamira Therapeutics does not pay dividends

What sector is Altamira Therapeutics in?

Altamira Therapeutics is in the Healthcare sector

What industry is Altamira Therapeutics in?

Altamira Therapeutics is in the Biotechnology industry

What country is Altamira Therapeutics based in?

Altamira Therapeutics is headquartered in Bermuda

When did Altamira Therapeutics go public?

Altamira Therapeutics's initial public offering (IPO) was on August 6, 2014

Is Altamira Therapeutics in the S&P 500?

No, Altamira Therapeutics is not included in the S&P 500 index

Is Altamira Therapeutics in the NASDAQ 100?

No, Altamira Therapeutics is not included in the NASDAQ 100 index

Is Altamira Therapeutics in the Dow Jones?

No, Altamira Therapeutics is not included in the Dow Jones index

When was Altamira Therapeutics's last earnings report?

Altamira Therapeutics's most recent earnings report was on Sep 8, 2021

When does Altamira Therapeutics report earnings?

The date for Altamira Therapeutics's next earnings report has not been announced yet
On this page